Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Cancer care crowdfunding increasingly common, but rarely successful

2.

Radioligand Therapy Set to Transform Oncology Care

3.

Hemihedral resection not necessary for neuroendocrine surgery after appendicitis

4.

No increased risk of childhood cancer near UK nuclear sites, study finds

5.

Timely 'Nudges' Can Help Encourage More End-of-Life Conversations in Cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot